VBI-001

N/A

Report date: 2022/05/16 11:29:42

Base Information

Drug NameVBI-001

Drug Alias NameAnti CD38 anti ICAM1 bsAb Virtuoso TherapeuticsCD38 X ICAM1 bsAb(Virtuoso Therapeutics)Anti-CD38 anti-ICAM1 bispecific antibody (Virtuoso Therapeutics)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsPhagocytes stimulantsT lymphocytes stimulants +[5]

TargetsLymphocyte differentiation antigen CD38Intercellular adhesion molecule-1

Therapy Area/IndicationsMultiple MyelomaLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVirtuoso Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesVirtuoso Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsMultiple MyelomaLymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A